Glasmacher Axel, Prentice Archibald, Gorschlüter Marcus, Engelhart Steffen, Hahn Corinna, Djulbegovic Benjamin, Schmidt-Wolf Ingo G H
Department of Internal Medicine I, University of Bonn, 53105 Bonn, Germany.
J Clin Oncol. 2003 Dec 15;21(24):4615-26. doi: 10.1200/JCO.2003.04.052.
Efficacy of antifungal prophylaxis has not yet been convincingly proven in numerous trials of various antifungals. New evidence and the anti-Aspergillus efficacy of itraconazole prompted a new look at the data for the prevention of invasive fungal infections.
Randomized, controlled studies with itraconazole for antifungal prophylaxis in neutropenic patients with hematologic malignancies were identified from electronic databases and hand searching.
Thirteen randomized trials included 3,597 patients who were assessable for invasive fungal infections. Itraconazole reduced the incidence of invasive fungal infection (mean relative risk reduction, 40% +/- 13%; P =.002), the incidence of invasive yeast infections (mean, 53% +/- 19%; P =.004) and the mortality from invasive fungal infections (mean, 35% +/- 17%; P =.04) significantly. The incidence of invasive Aspergillus infections was only reduced in trials using the itraconazole cyclodextrine solution (mean, 48% +/- 21%; P =.02) and not itraconazole capsules (mean, 75% +/- 73% increase; P =.3). The overall mortality was not changed. Adverse effects were rare, hypokalemia was noted in three studies, and a higher rate of drug discontinuation was found in trials that compared itraconazole cyclodextrine solution to a control without cyclodextrine. The effect of prophylaxis was clearly associated with a higher bioavailable dose of itraconazole.
Antifungal prophylaxis with itraconazole effectively prevents proven invasive fungal infections and-shown for the first time for antifungal prophylaxis-reduces mortality from these infections and the rate of invasive Aspergillus infections in neutropenic patients with hematologic malignancies. Adequate doses of the oral cyclodextrine solution (at least 400 mg/d) or i.v. formulations (200 mg/d) of itraconazole are necessary for these effects.
在众多关于各种抗真菌药物的试验中,抗真菌预防的疗效尚未得到令人信服的证实。新的证据以及伊曲康唑的抗曲霉菌疗效促使人们重新审视预防侵袭性真菌感染的数据。
通过电子数据库检索和手工检索,确定了在血液系统恶性肿瘤中性粒细胞减少患者中使用伊曲康唑进行抗真菌预防的随机对照研究。
13项随机试验纳入了3597例可评估侵袭性真菌感染的患者。伊曲康唑显著降低了侵袭性真菌感染的发生率(平均相对风险降低40%±13%;P = 0.002)、侵袭性酵母菌感染的发生率(平均53%±19%;P = 0.004)以及侵袭性真菌感染导致的死亡率(平均35%±17%;P = 0.04)。侵袭性曲霉菌感染的发生率仅在使用伊曲康唑环糊精溶液的试验中有所降低(平均48%±21%;P = 0.02),而在使用伊曲康唑胶囊的试验中未降低(平均增加75%±73%;P = 0.3)。总体死亡率未改变。不良反应罕见,三项研究中发现有低钾血症,并且在将伊曲康唑环糊精溶液与无环糊精对照进行比较的试验中,药物停用率较高。预防效果与伊曲康唑更高的生物利用度剂量明显相关。
伊曲康唑进行抗真菌预防可有效预防已证实的侵袭性真菌感染,并且首次表明对血液系统恶性肿瘤中性粒细胞减少患者,抗真菌预防可降低这些感染导致的死亡率以及侵袭性曲霉菌感染的发生率。为获得这些效果,需要足够剂量的伊曲康唑口服环糊精溶液(至少400毫克/天)或静脉制剂(200毫克/天)。